---
annotation-target: Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-30T02:28:24.110Z","updated":"2022-08-30T02:28:24.110Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":3608,"end":3896},{"type":"TextQuoteSelector","exact":" cytarabine and anthracyclines. Five-year overall survival is below 30%, which has partly been attributed to cytarabine resistance. Preclinical data suggest that the addition of hydroxyurea potentiates cytarabine efficacy by increasing ara-CTP levels through targeted inhibition of SAMHD1","prefix":"on combination chemotherapy with","suffix":". Objectives In this phase-1 tri"}]}]}
>```
>%%
>*%%PREFIX%%on combination chemotherapy with%%HIGHLIGHT%% ==cytarabine and anthracyclines. Five-year overall survival is below 30%, which has partly been attributed to cytarabine resistance. Preclinical data suggest that the addition of hydroxyurea potentiates cytarabine efficacy by increasing ara-CTP levels through targeted inhibition of SAMHD1== %%POSTFIX%%. Objectives In this phase-1 tri*
>%%LINK%%[[#^m63eog7iwct|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^m63eog7iwct


>%%
>```annotation-json
>{"created":"2022-08-30T02:29:48.597Z","updated":"2022-08-30T02:29:48.597Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":6111,"end":6179},{"type":"TextQuoteSelector","exact":". The overall prognosis is poor but varies with risk-group and age. ","prefix":" a median age of ~70 years[1, 2]","suffix":"In patients fit for intensive ch"}]}]}
>```
>%%
>*%%PREFIX%%a median age of ~70 years[1, 2]%%HIGHLIGHT%% ==. The overall prognosis is poor but varies with risk-group and age.== %%POSTFIX%%In patients fit for intensive ch*
>%%LINK%%[[#^pleyyp589|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^pleyyp589


>%%
>```annotation-json
>{"created":"2022-08-30T02:32:10.991Z","updated":"2022-08-30T02:32:10.991Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":6509,"end":7151},{"type":"TextQuoteSelector","exact":" Standard of care for non-promyelocytic AML consists of intensive induction and consolidation chemotherapy with cytarabine (ara-C) and an anthracycline, frequently daunorubicin[4, 5]. Multiple attempts have been made to improve outcome by adding novel components to the daunorubicin + ara-C backbone, but with little success. Important exceptions are the FLT3-inhibitor midostaurin and gemtuzumab ozogamicin in patients with somatic mutations in FLT3 and core-binding factor AML (CBF-AML), respectively[4, 6-8]. Risk-adapted hematopoietic stem cell transplantation (allo-HSCT) should be considered after achieving complete remission[4, 6, 9].","prefix":"ated features in the elderly[3].","suffix":" High-dose ara-C is a critical p"}]}]}
>```
>%%
>*%%PREFIX%%ated features in the elderly[3].%%HIGHLIGHT%% ==Standard of care for non-promyelocytic AML consists of intensive induction and consolidation chemotherapy with cytarabine (ara-C) and an anthracycline, frequently daunorubicin[4, 5]. Multiple attempts have been made to improve outcome by adding novel components to the daunorubicin + ara-C backbone, but with little success. Important exceptions are the FLT3-inhibitor midostaurin and gemtuzumab ozogamicin in patients with somatic mutations in FLT3 and core-binding factor AML (CBF-AML), respectively[4, 6-8]. Risk-adapted hematopoietic stem cell transplantation (allo-HSCT) should be considered after achieving complete remission[4, 6, 9].== %%POSTFIX%%High-dose ara-C is a critical p*
>%%LINK%%[[#^rj6jf496pi|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rj6jf496pi


>%%
>```annotation-json
>{"created":"2022-08-30T02:33:19.625Z","updated":"2022-08-30T02:33:19.625Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":7152,"end":7906},{"type":"TextQuoteSelector","exact":"High-dose ara-C is a critical part of AML therapy, particularly during post-remission consolidation[4, 6, 10, 11]. Ara-C is a deoxycytidine analogue that is transported into leukemic cells by the equilibrative nucleoside transporter 2 (hENT2), and is subsequently mono-, di- and triphosphorylated by deoxytidine kinase (dCK), UMP/CMP kinase, and Nucleotide diphosphate kinases 1 and 2 (NDPK1/2), respectively. Ara-C and ara-CMP can be inactivated through deamination by cytidine deaminase (CDA) and dCMP deaminase (DCTD), and ara-CMP can be dephosphorylated by cytosolic 5′-nucleotidases. Ara-CTP is a substrate for DNA polymerases and can be incorporated into DNA during replication, perturbing further DNA elongation and triggering DNA damage responses","prefix":"ng complete remission[4, 6, 9]. ","suffix":"[12]. Failure to  This article i"}]}]}
>```
>%%
>*%%PREFIX%%ng complete remission[4, 6, 9].%%HIGHLIGHT%% ==High-dose ara-C is a critical part of AML therapy, particularly during post-remission consolidation[4, 6, 10, 11]. Ara-C is a deoxycytidine analogue that is transported into leukemic cells by the equilibrative nucleoside transporter 2 (hENT2), and is subsequently mono-, di- and triphosphorylated by deoxytidine kinase (dCK), UMP/CMP kinase, and Nucleotide diphosphate kinases 1 and 2 (NDPK1/2), respectively. Ara-C and ara-CMP can be inactivated through deamination by cytidine deaminase (CDA) and dCMP deaminase (DCTD), and ara-CMP can be dephosphorylated by cytosolic 5′-nucleotidases. Ara-CTP is a substrate for DNA polymerases and can be incorporated into DNA during replication, perturbing further DNA elongation and triggering DNA damage responses== %%POSTFIX%%[12]. Failure to  This article i*
>%%LINK%%[[#^5s6jz7q5mu4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5s6jz7q5mu4


>%%
>```annotation-json
>{"created":"2022-08-30T02:35:32.636Z","updated":"2022-08-30T02:35:32.636Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":8681,"end":9404},{"type":"TextQuoteSelector","exact":"Mechanistically, we have shown that hydroxyurea causes dNTP imbalances by reducing dATP and dGTP levels without affecting dCTP. In parallel, deoxycytidine kinase (dCK) is activated[24]. Hence, neither allosteric inhibition of dCK nor substrate competition at DNA polymerase by dCTP are expected effects of hydroxyurea treatment. Hydroxyurea has pleiotropic effects[26], with potent SAMHD1 inhibition already at concentrations of 20 μM[14], while reversible S-phase cell cycle arrest is increasingly seen at higher concentrations, reported in the millimolar range[27]. The plasma levels reached in adults dosed with 1 g hydroxyurea is expected to fully inhibit SAMHD1 while only having a limited effect on cell cycling[28]. ","prefix":"r ara-CTP accumulation[24, 25]. ","suffix":"In support of the addition of RN"}]}]}
>```
>%%
>*%%PREFIX%%r ara-CTP accumulation[24, 25].%%HIGHLIGHT%% ==Mechanistically, we have shown that hydroxyurea causes dNTP imbalances by reducing dATP and dGTP levels without affecting dCTP. In parallel, deoxycytidine kinase (dCK) is activated[24]. Hence, neither allosteric inhibition of dCK nor substrate competition at DNA polymerase by dCTP are expected effects of hydroxyurea treatment. Hydroxyurea has pleiotropic effects[26], with potent SAMHD1 inhibition already at concentrations of 20 μM[14], while reversible S-phase cell cycle arrest is increasingly seen at higher concentrations, reported in the millimolar range[27]. The plasma levels reached in adults dosed with 1 g hydroxyurea is expected to fully inhibit SAMHD1 while only having a limited effect on cell cycling[28].== %%POSTFIX%%In support of the addition of RN*
>%%LINK%%[[#^27powd0x3w6|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^27powd0x3w6


>%%
>```annotation-json
>{"created":"2022-08-30T02:37:54.115Z","updated":"2022-08-30T02:37:54.115Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":9450,"end":9815},{"type":"TextQuoteSelector","exact":"he allosteric RNRi fludarabine had been reported to clinically increase ara-CTP accumulation[29], which led to the establishment of AML-treatment strategies combining fludarabine and ara-C[30]. However, more recent data suggest that fludarabine, in contrast to hydroxyurea, does not increase the ara-C sensitivity or the ara-CTP levels in cellular models of AML[24]","prefix":"the addition of RNRi to ara-C, t","suffix":". Another previously employed st"}]}]}
>```
>%%
>*%%PREFIX%%the addition of RNRi to ara-C, t%%HIGHLIGHT%% ==he allosteric RNRi fludarabine had been reported to clinically increase ara-CTP accumulation[29], which led to the establishment of AML-treatment strategies combining fludarabine and ara-C[30]. However, more recent data suggest that fludarabine, in contrast to hydroxyurea, does not increase the ara-C sensitivity or the ara-CTP levels in cellular models of AML[24]== %%POSTFIX%%. Another previously employed st*
>%%LINK%%[[#^9tnqsxjz2i|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^9tnqsxjz2i


>%%
>```annotation-json
>{"created":"2022-08-30T02:38:48.917Z","updated":"2022-08-30T02:38:48.917Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":13846,"end":13855},{"type":"TextQuoteSelector","exact":"Endpoints","prefix":"vided written informed consent. ","suffix":" Primary endpoints were safety a"}]}]}
>```
>%%
>*%%PREFIX%%vided written informed consent.%%HIGHLIGHT%% ==Endpoints== %%POSTFIX%%Primary endpoints were safety a*
>%%LINK%%[[#^ctv5sqzd16|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ctv5sqzd16


>%%
>```annotation-json
>{"created":"2022-08-30T02:38:59.276Z","updated":"2022-08-30T02:38:59.276Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":13965,"end":14041},{"type":"TextQuoteSelector","exact":"including time to hematopoietic recovery (ANC 0.5 and 1.0 x 109/L; platelets","prefix":"icities according to CTCAE v5), ","suffix":"  This article is protected by c"}]}]}
>```
>%%
>*%%PREFIX%%icities according to CTCAE v5),%%HIGHLIGHT%% ==including time to hematopoietic recovery (ANC 0.5 and 1.0 x 109/L; platelets== %%POSTFIX%%This article is protected by c*
>%%LINK%%[[#^sgguuz9j1dq|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^sgguuz9j1dq


>%%
>```annotation-json
>{"created":"2022-08-30T02:39:19.373Z","updated":"2022-08-30T02:39:19.373Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":14211,"end":14480},{"type":"TextQuoteSelector","exact":"Secondary endpoints were response according to European Leukemia Net (ELN) criteria[4] and measurable residual disease (MRD) <0.1% following treatment cycle 2, and ara-CTP accumulation in peripheral blasts during the first chemotherapy cycle with or without hydroxyurea","prefix":"rt of the cycle until recovery. ","suffix":". An additional explorative endp"}]}]}
>```
>%%
>*%%PREFIX%%rt of the cycle until recovery.%%HIGHLIGHT%% ==Secondary endpoints were response according to European Leukemia Net (ELN) criteria[4] and measurable residual disease (MRD) <0.1% following treatment cycle 2, and ara-CTP accumulation in peripheral blasts during the first chemotherapy cycle with or without hydroxyurea== %%POSTFIX%%. An additional explorative endp*
>%%LINK%%[[#^xm9edduod4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xm9edduod4


>%%
>```annotation-json
>{"created":"2022-08-30T02:40:01.357Z","updated":"2022-08-30T02:40:01.357Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":19929,"end":19958},{"type":"TextQuoteSelector","exact":"Prism 9.2.0, GraphPad Softwar","prefix":"al-Wallis tests were performed (","suffix":"e, San Diego, CA, USA). Role of "}]}]}
>```
>%%
>*%%PREFIX%%al-Wallis tests were performed (%%HIGHLIGHT%% ==Prism 9.2.0, GraphPad Softwar== %%POSTFIX%%e, San Diego, CA, USA). Role of*
>%%LINK%%[[#^mpw31dyzay|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mpw31dyzay


>%%
>```annotation-json
>{"created":"2022-08-30T02:41:36.360Z","updated":"2022-08-30T02:41:36.360Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":29406,"end":29874},{"type":"TextQuoteSelector","exact":"It is conceivable that the addition of hydroxyurea potentiates the risk of ara-C-related adverse events. However, the observed toxicities and time to hematopoietic recovery were in line with expected outcomes for patients undergoing intensive chemotherapy for AML[47] and did not delay subsequent cycles of chemotherapy or time-to-HSCT. This might at least partially be explained by the low expression levels of SAMHD1 in healthy bone-marrow progenitors including HSC.","prefix":" and 25-30%, respectively[46].  ","suffix":" The lack of excess myelosuppres"}]}]}
>```
>%%
>*%%PREFIX%%and 25-30%, respectively[46].%%HIGHLIGHT%% ==It is conceivable that the addition of hydroxyurea potentiates the risk of ara-C-related adverse events. However, the observed toxicities and time to hematopoietic recovery were in line with expected outcomes for patients undergoing intensive chemotherapy for AML[47] and did not delay subsequent cycles of chemotherapy or time-to-HSCT. This might at least partially be explained by the low expression levels of SAMHD1 in healthy bone-marrow progenitors including HSC.== %%POSTFIX%%The lack of excess myelosuppres*
>%%LINK%%[[#^1gtuobvt0h8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^1gtuobvt0h8


>%%
>```annotation-json
>{"created":"2022-08-30T02:42:49.864Z","updated":"2022-08-30T02:42:49.864Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":33702,"end":33995},{"type":"TextQuoteSelector","exact":" However, administering 1000 mg of hydroxyurea one hour prior to ara-C infusion significantly increased relative peak ara-CTP levels in circulating patient blasts by a factor of 1.5, and those results could be confirmed by treating diagnostic patient blasts with ara-C and hydroxyurea ex vivo.","prefix":" peak ara-CTP levels do not[17].","suffix":" As hydroxyurea was either given"}]}]}
>```
>%%
>*%%PREFIX%%peak ara-CTP levels do not[17].%%HIGHLIGHT%% ==However, administering 1000 mg of hydroxyurea one hour prior to ara-C infusion significantly increased relative peak ara-CTP levels in circulating patient blasts by a factor of 1.5, and those results could be confirmed by treating diagnostic patient blasts with ara-C and hydroxyurea ex vivo.== %%POSTFIX%%As hydroxyurea was either given*
>%%LINK%%[[#^sgz5wwfiq|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^sgz5wwfiq


>%%
>```annotation-json
>{"created":"2022-08-30T02:43:35.211Z","updated":"2022-08-30T02:43:35.211Z","document":{"title":"Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial","link":[{"href":"urn:x-pdf:f01968467d9255c687bd32b99890cf9e"},{"href":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf"}],"documentFingerprint":"f01968467d9255c687bd32b99890cf9e"},"uri":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Journal of Internal Medicine - 2022 - J dersten - Targeting SAMHD1 with hydroxyurea in first%E2%80%90line cytarabine%E2%80%90based therapy.pdf","selector":[{"type":"TextPositionSelector","start":34720,"end":35480},{"type":"TextQuoteSelector","exact":"A recent publication suggests that treatment of AML with nucleoside analogues might induce differentiation through hyperactivation of ribonucleotide reductase, leading to a dNTP pool imbalance which could be further aggravated by depletion of SAMHD1[52]. Hence, ara-C-mediated differentiation that is increased by SAMHD1 inhibition might be an alternative explanation for the observed efficacy to achieve MRD negativity in our trial. However, in our previous studies, we neither observed effects of SAMHD1 depletion on protein levels of RNR subunits nor on dNTP pool balances[19, 24]. In conclusion, the high rate of complete remission and MRD negativity together with the pharmacokinetic and ex vivo evidence suggest that the efficacy of cytarabine-based AML ","prefix":" of ara-C and hydroxyurea[24].  ","suffix":"treatment can be enhanced by the"}]}]}
>```
>%%
>*%%PREFIX%%of ara-C and hydroxyurea[24].%%HIGHLIGHT%% ==A recent publication suggests that treatment of AML with nucleoside analogues might induce differentiation through hyperactivation of ribonucleotide reductase, leading to a dNTP pool imbalance which could be further aggravated by depletion of SAMHD1[52]. Hence, ara-C-mediated differentiation that is increased by SAMHD1 inhibition might be an alternative explanation for the observed efficacy to achieve MRD negativity in our trial. However, in our previous studies, we neither observed effects of SAMHD1 depletion on protein levels of RNR subunits nor on dNTP pool balances[19, 24]. In conclusion, the high rate of complete remission and MRD negativity together with the pharmacokinetic and ex vivo evidence suggest that the efficacy of cytarabine-based AML== %%POSTFIX%%treatment can be enhanced by the*
>%%LINK%%[[#^yodc0rarki|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^yodc0rarki
